RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

AstraZeneca662 enrolled

Overview

In the RELEVANCE study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage III NSCLC population in Canada across several Canadian cancer centres. Subsequent analyses will examine treatment patterns and clinical outcomes, including overall survival, for these patients, stratified by durvalumab regimen or non-durvalumab regimen during the time of the PACIFIC Patient Support Program.

Study Type

OBSERVATIONAL

Enrollment

662

Conditions

Non-small Cell Lung Cancer

Interventions

DurvalumabDRUG

Chemoradiotherapy plus durvalumab

Eligibility

Sex: ALLMin age: 18 YearsMax age: 130 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged 18 years or older * Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent (stage III) disease between November 1, 2017 and December 31, 2019 at the centre (Note: durvalumab uptake rate requires a secondary index date, such as initiation of CRT before availability of durvalumab in May 2018) Exclusion Criteria: * Patients treated with durvalumab in clinical studies prior to the start date * Clinical trial patients where treatments received are blinded in the patient medical records

Locations (5)

University of Calgary

Calgary, Alberta, Canada

BC Cancer

Vancouver, British Columbia, Canada

Queen Elizabeth (QE) II Health Sciences Centre

Halifax, Nova Scotia, Canada

The Ottawa Hospital

Ottawa, Ontario, Canada